These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 7556401)
1. kappa-Opioid receptor agonist protects against ischemic reduction of 2-deoxyglucose uptake in morphine-tolerant rats. Shibata S; Tominaga K; Watanabe S Eur J Pharmacol; 1995 Jun; 279(2-3):197-202. PubMed ID: 7556401 [TBL] [Abstract][Full Text] [Related]
2. Effects of naloxone, morphine and kappa-opioid receptor agonists on hypoxia/hypoglycemia-induced reduction of 2-deoxyglucose uptake in hippocampal slices from U-50,488H-tolerant rats. Shibata S; Tominaga K; Watanabe S Neurosci Lett; 1994 Dec; 182(2):155-8. PubMed ID: 7715801 [TBL] [Abstract][Full Text] [Related]
3. Analgesic and discriminative stimulus properties of U-62,066E, the selective kappa-opioid receptor agonist, in the rat. Ohno M; Yamamoto T; Ueki S Psychopharmacology (Berl); 1992; 106(1):31-8. PubMed ID: 1346721 [TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of buprenorphine, a mixed agonist-antagonist with kappa 3 analgesia. Pick CG; Peter Y; Schreiber S; Weizman R Brain Res; 1997 Jan; 744(1):41-6. PubMed ID: 9030411 [TBL] [Abstract][Full Text] [Related]
5. The NMDA receptor antagonist MK-801 differentially modulates mu and kappa opioid actions in spinal cord in vitro. Feng J; Kendig JJ Pain; 1996 Aug; 66(2-3):343-9. PubMed ID: 8880858 [TBL] [Abstract][Full Text] [Related]
6. The effect of mu and kappa opioid receptor agonists on cAMP level in hippocampus of kainic acid-treated rats. Dziedzicka-Wasylewska M; Przewłocki R Pol J Pharmacol; 1995; 47(2):121-6. PubMed ID: 8688884 [TBL] [Abstract][Full Text] [Related]
7. Differential cross-tolerance to mu and kappa opioid agonists in morphine-tolerant rats responding under a schedule of food presentation. Picker MJ; Negus SS; Powell KR Psychopharmacology (Berl); 1991; 103(1):129-35. PubMed ID: 1848712 [TBL] [Abstract][Full Text] [Related]
8. Cross-tolerance to acute administration of mu and kappa opioid agonists at the spinal cord level in the rat. Laurido C; Hernandez A; Perez H Int J Neurosci; 1996 Nov; 87(3-4):191-9. PubMed ID: 9003979 [TBL] [Abstract][Full Text] [Related]
9. Discriminative stimulus properties of U50,488 and morphine: effects of training dose on stimulus substitution patterns produced by mu and kappa opioid agonists. Picker MJ; Doty P; Negus SS; Mattox SR; Dykstra LA J Pharmacol Exp Ther; 1990 Jul; 254(1):13-22. PubMed ID: 2164087 [TBL] [Abstract][Full Text] [Related]
10. Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action. Millan MJ; Członkowski A; Lipkowski A; Herz A J Pharmacol Exp Ther; 1989 Oct; 251(1):342-50. PubMed ID: 2571723 [TBL] [Abstract][Full Text] [Related]
11. Influence of chronic lithium treatment upon the motivational effects of opioids: alteration in the effects of mu- but not kappa-opioid receptor ligands. Shippenberg TS; Herz A J Pharmacol Exp Ther; 1991 Mar; 256(3):1101-6. PubMed ID: 1848627 [TBL] [Abstract][Full Text] [Related]
12. The role of nitric oxide in the development of opioid withdrawal induced by naloxone after acute treatment with mu- and kappa-opioid receptor agonists. Capasso A; Sorrentino L; Pinto A Eur J Pharmacol; 1998 Oct; 359(2-3):127-31. PubMed ID: 9832382 [TBL] [Abstract][Full Text] [Related]
13. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors. Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171 [TBL] [Abstract][Full Text] [Related]
14. Activation of kappa opioid receptors by U50488H and morphine enhances the release of substance P from rat trigeminal nucleus slices. Suarez-Roca H; Maixner W J Pharmacol Exp Ther; 1993 Feb; 264(2):648-53. PubMed ID: 7679733 [TBL] [Abstract][Full Text] [Related]
15. Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception. Stevenson GW; Folk JE; Linsenmayer DC; Rice KC; Negus SS J Pharmacol Exp Ther; 2003 Dec; 307(3):1054-64. PubMed ID: 14557380 [TBL] [Abstract][Full Text] [Related]
16. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice. Baker AK; Meert TF J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687 [TBL] [Abstract][Full Text] [Related]
17. Opioid kappa receptors and the secretion of prolactin (PRL) and growth hormone (GH) in the rat. I. Effects of opioid kappa receptor agonists bremazocine and U-50,488 on secretion of PRL and GH: comparison with morphine. Krulich L; Koenig JI; Conway S; McCann SM; Mayfield MA Neuroendocrinology; 1986; 42(1):75-81. PubMed ID: 3001565 [TBL] [Abstract][Full Text] [Related]
18. U-50,488, a selective kappa opioid agonist: comparison to other reputed kappa agonists. Von Voigtlander PF; Lewis RA Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):467-70. PubMed ID: 6298890 [TBL] [Abstract][Full Text] [Related]
19. The site of anti-arthritic action of the kappa-opioid, U-50, 488H, in adjuvant arthritis: importance of local administration. Wilson JL; Nayanar V; Walker JS Br J Pharmacol; 1996 Aug; 118(7):1754-60. PubMed ID: 8842441 [TBL] [Abstract][Full Text] [Related]
20. Effects of morphine in rats treated chronically with U-50,488 H, a kappa opioid receptor agonist. Bhargava HN; Ramarao P; Gulati A Eur J Pharmacol; 1989 Mar; 162(2):257-64. PubMed ID: 2542058 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]